Effects of Comprehensive Care in Patients with Multiple Myeloma with Cardiac Dysfunction

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2021 Jun 21

PMID 34150066

Authors

Jinglu Xu

Ru Bai

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the effect of comprehensive care on cardiac and renal function indices, treatment compliance, self-care ability and quality of life in patients with multiple myeloma combined with cardiac dysfunction.

Methods: A total of 53 patients diagnosed with multiple myeloma combined with cardiac dysfunction admitted to our hospital were enrolled and divided into the control group (n=25) and the experimental group (n=28) by the method of random number table. Patients in the control group were given routine nursing care, while patients in the experimental group were given comprehensive care on the basis of the routine nursing care of the control group. The changes in cardiac and renal function indices, treatment compliance, self-care ability, and quality of life were observed after intervention of different nursing methods in the two groups.

Results: The levels of left ventricular ejection fraction, brain natriuretic peptide, N-terminal pro-brain natriuretic peptide, glomerular filtration rate, serum creatinine, and uric acid in the experimental group were significantly improved after intervention, showing significant differences between the two groups (<0.05). The treatment compliance in the experimental group (92.86%) was significantly higher than that in the control group (68%). The scores of self-care ability and quality of life in the experimental group were significantly higher than those in the control group after intervention (<0.05).

Conclusion: Comprehensive care can significantly help to improve cardiac and renal functions, treatment compliance, self-care ability and quality of life in patients with multiple myeloma combined with cardiac dysfunction, which is of great clinical significance.

References

Kang H, Choi E . Factors influencing quality of life in patients with multiple myeloma. Contemp Nurse. 2019; 55(2-3):109-121. DOI: 10.1080/10376178.2019.1623699. View

Landgren O, Iskander K . Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med. 2017; 281(4):365-382. DOI: 10.1111/joim.12590. View

Cormican O, Dowling M . Living with relapsed myeloma: Symptoms and self-care strategies. J Clin Nurs. 2017; 27(7-8):1713-1721. PMC: 5947652. DOI: 10.1111/jocn.14232. View

Kyle R, Rajkumar S . Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2008; 23(1):3-9. PMC: 2627786. DOI: 10.1038/leu.2008.291. View

Zhou F, Ling C, Guo L, Wei W, Li L, Shi H . Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure. Leuk Lymphoma. 2014; 55(10):2271-6. DOI: 10.3109/10428194.2014.887711. View

Bilotti E, Faiman B, Richards T, Tariman J, Miceli T, Rome S . Survivorship care guidelines for patients living with multiple myeloma: consensus statements of the International Myeloma Foundation Nurse Leadership Board. Clin J Oncol Nurs. 2011; 15 Suppl:5-8. PMC: 3422736. DOI: 10.1188/11.S1.CJON.5-8. View

Kistler K, Kalman J, Sahni G, Murphy B, Werther W, Rajangam K . Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational, Retrospective, Cohort Study. Clin Lymphoma Myeloma Leuk. 2016; 17(2):89-96.e3. DOI: 10.1016/j.clml.2016.11.009. View

Sivaraj D, Green M, Gasparetto C . Panobinostat for the management of multiple myeloma. Future Oncol. 2016; 13(6):477-488. DOI: 10.2217/fon-2016-0329. View

Sangani R, Butler M, Kirchner H, Berger A, Stamm J . Echocardiography-Defined Pulmonary Hypertension in Multiple Myeloma: Risk Factors and Impact on Outcomes. South Med J. 2016; 109(5):282-9. DOI: 10.14423/SMJ.0000000000000461. View

10.

Rajkumar S, Kumar S . Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc. 2016; 91(1):101-19. PMC: 5223450. DOI: 10.1016/j.mayocp.2015.11.007. View

11.

Bringhen S, Milan A, Ferri C, Wasch R, Gay F, Larocca A . Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica. 2018; 103(9):1422-1432. PMC: 6119131. DOI: 10.3324/haematol.2018.191288. View

12.

Bilotti E, Gleason C, McNeill A . Routine health maintenance in patients living with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. Clin J Oncol Nurs. 2011; 15 Suppl:25-40. DOI: 10.1188/11.S1.CJON.25-40. View

13.

da Silva Filho M, Forsti A, Weinhold N, Meziane I, Campo C, Huhn S . Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma. Leukemia. 2016; 31(8):1735-1742. DOI: 10.1038/leu.2016.387. View

14.

Kazandjian D . Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2017; 43(6):676-681. PMC: 5283695. DOI: 10.1053/j.seminoncol.2016.11.004. View

15.

Falk R, Alexander K, Liao R, Dorbala S . AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol. 2016; 68(12):1323-41. DOI: 10.1016/j.jacc.2016.06.053. View

16.

Ria R, Reale A, Vacca A . Novel agents and new therapeutic approaches for treatment of multiple myeloma. World J Methodol. 2014; 4(2):73-90. PMC: 4202483. DOI: 10.5662/wjm.v4.i2.73. View

17.

Dispenzieri A, Kyle R, Gertz M, Therneau T, Miller W, Chandrasekaran K . Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003; 361(9371):1787-9. DOI: 10.1016/S0140-6736(03)13396-X. View

18.

Cornell R, Kassim A . Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplant. 2016; 51(4):479-91. PMC: 4827007. DOI: 10.1038/bmt.2015.307. View

19.

Maharaj S, Chang S, Seegobin K, Serrano-Santiago I, Zuberi L . Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma. Expert Rev Anticancer Ther. 2017; 17(7):585-591. DOI: 10.1080/14737140.2017.1330153. View

20.

Kosmala A, Bley T, Petritsch B . Imaging of Multiple Myeloma. Rofo. 2019; 191(9):805-816. DOI: 10.1055/a-0864-2084. View